Pfizer's Bold Move into the Weight Loss Market: Oral GLP-1 Medications In this episode of 'The Downsized,' host Christopher Durham delves into Pfizer's latest efforts to enter the competitive weight loss market, focusing on the development of oral GLP-1 medications. As Pfizer prepares to challenge industry leaders Novo Nordisk and Eli Lilly, Durham reviews the company's Q3 earnings call and their unveiling of three new drug candidates. Emphasizing the potential impact of oral options on patient accessibility and treatment costs, the episode also explains the roles of GLP-1 and GIP in weight loss and diabetes management. Highlighting Pfizer's strategic advantage, Durham discusses how these innovative treatments could drive market competition and make life-changing medications more affordable and accessible. The episode concludes with a hopeful perspective on the evolving landscape of obesity treatment and encourages viewers to stay informed through the channel’s updates. DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized/join DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store We use Mochi Health: https://joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8. 00:00 Introduction 01:10 Pfizer's Ambitious Plans for Weight Loss Market 03:04 Understanding GLP-1 and GIP Hormones 04:26 Pfizer's Latest Developments and Drug Candidates 07:23 Impact on Obesity Treatment and Market Competition 11:36 Financial Performance and Market Potential 13:12 Conclusion and Future Outlook

Related Videos :







GLP-1 Market Disrupter? Pfizer to Take on Eli Lilly & Novo Nordisk! [fEztwQcoM]

GLP-1 Market Disrupter? Pfizer to Take on Eli Lilly & Novo Nordisk! [fEztwQcoM]

Pfizer's Bold Move into the Weight Loss Market: Oral GLP-1 Medications In this episode of 'The Downsized,' host Christopher Durham delves into Pfizer's latest efforts to enter the competitive weight loss market, focusing on the development of oral GLP-1 medications. As Pfizer prepares to challenge industry leaders Novo Nordisk and Eli Lilly, Durham reviews the company's Q3 earnings call and their unveiling of three new drug candidates. Emphasizing the potential impact of oral options on patient accessibility and treatment costs, the episode also explains the roles of GLP-1 and GIP in weight loss and diabetes management. Highlighting Pfizer's strategic advantage, Durham discusses how these innovative treatments could drive market competition and make life-changing medications more affordable and accessible. The episode concludes with a hopeful perspective on the evolving landscape of obesity treatment and encourages viewers to stay informed through the channel’s updates. DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized/join DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store We use Mochi Health: https://joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8. 00:00 Introduction 01:10 Pfizer's Ambitious Plans for Weight Loss Market 03:04 Understanding GLP-1 and GIP Hormones 04:26 Pfizer's Latest Developments and Drug Candidates 07:23 Impact on Obesity Treatment and Market Competition 11:36 Financial Performance and Market Potential 13:12 Conclusion and Future Outlook

Related Videos :

Aired: December 3rd 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now